Gossamer Bio, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $48.5M | $114.7M | $0 | $0 | — |
| Operating income | -$170.7M | -$59.9M | -$183.8M | -$218.6M | -$216.1M |
| Operating expenses | $219.2M | $174.6M | $183.8M | $218.6M | $216.1M |
| Cash from operations | -$171.3M | -$3.5M | -$159.2M | -$187.0M | -$188.9M |
| Capital expenditure | $79,000 | $0 | $0 | $410,000 | $1.5M |
| Free cash flow | -$171.3M | -$3.5M | -$159.2M | -$187.4M | -$190.4M |
| Total assets | $172.2M | $315.3M | $311.9M | $272.4M | $343.7M |
| Total liabilities | $295.0M | $285.8M | $249.1M | $260.4M | $222.2M |
Shares outstanding 234.7M · Free float 100.0%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.